Genetic Determinants of Akt-induced Transformation

Akt 诱导转化的遗传决定因素

• 批准号: 7280486
• 负责人: Eugene S Kandel
• 金额: $ 13.78万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7280486
• 关键词: 1-Phosphatidylinositol 3-Kinase; 4-Hydroxy-Tamoxifen; Affect; Automobile Driving; Binding; Biochemical Genetics; Biological; Biological Assay; Biological Models; Cell Cycle; Cell Line; Cell Survival; Cell membrane; Cell physiology; Cells; Cyclic AMP-Dependent Protein Kinases; DNA; Diagnostic; Engineering; Estrogen Receptors; Event; Excision; Exhibits; Fibroblasts; Foundations; Genes; Genetic; Genetic Determinism; Genetic Screening; Genome; Glucocorticoids; Growth Factor; Hand; High Prevalence; Homologous Gene; Human; Insertional Mutagenesis; Investigation; Laboratories; Length; Ligand Binding Domain; Lipids; MAPK1 gene; MAPK3 gene; Malignant Neoplasms; Membrane; Metabolism; Modeling; Mus; Nature; Normal Cell; Numbers; Oncogenes; Oncogenic; Other Genetics; PTEN gene; Pathway interactions; Phenotype; Phosphoinositide-3-Kinase, Catalytic, Gamma Polypeptide; Phospholipids; Phosphoric Monoester Hydrolases; Phosphotransferases; Prevention; Procedures; Process; Production; Protein Isoforms; Protein Kinase; Protein Overexpression; Protein-Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins c-akt; RNA; Receptor Protein-Tyrosine Kinases; Relaxation; Retroviral Vector; Role; Running; Serum; Signal Transduction; Substrate Specificity; System; Tissue Microarray; Validation; adipocyte differentiation; base; cancer therapy; cell type; experience; functional status; gene discovery; improved; insight; myristoylation; prevent; programs; promoter; research study; response; sugar; synergism; therapeutic target; tool; tumor; tumorigenesis; vector

DESCRIPTION (provided by applicant): The protein kinase Akt is commonly up-regulated in human cancers, leading to increased survival and proliferation, as well as to the relaxation of controls on cell cycle and genome integrity in various cell types. On the other hand, in some model systems Akt promotes terminal differentiation. I hypothesize that the status of additional cellular factors determines whether activated Akt contributes to tumorigenesis or to differentiation. Due to the pleiotropic role of Akt in normal cells, the events that cooperate with Akt in oncogenesis are likely to be more tractable therapeutic targets than Akt itself. We have established a model system in which Akt activation alone is unable to cause transformation, but can do so in cooperation with other genetic events. The cells harboring such events could be easily distinguished by the ability to form foci in confluent cultures. We have identified the accumulation of Raf as one such event: Akt and Raf cooperate in the activation of some downstream components of Raf-dependent signaling. We will investigate the mechanism of the Akt-Raf connection, as well as the essential downstream events in this cooperative process. In the same system we will also use an unbiased genetic screen to identify additional genetic events that may cooperate with activated Akt in oncogenic transformation. We have gained valuable experience with insertional mutagenesis as a foundation for gene discovery projects. We will conduct genome-wide insertional mutagenesis with a modified retroviral vector, which carries a promoter oriented towards the host DNA, driving production of full-length, truncated or anti-sense products of host genes. The vector is engineered to permit excision of the promoter, allowing for unequivocal validation of the promoter insertion as the cause of the transformed phenotype. The insertional events cooperating with Akt in transformation will be identified and the roles of the affected proteins in transformation and differentiation will be studied further, including analysis of direct interaction with Akt and components of the Raf pathway. We will examine the roles of the newly characterized factors in transformation by various oncogenes that are known to up-regulate Akt. The status of these factors in human cancers will be studied using RNA and tissue arrays. In the long run, the project will identify potential targets and markers for cancer therapy and provide the insights into the mechanisms of oncogenic transformation.

描述（由申请人提供）：蛋白激酶Akt在人类癌症中通常上调，导致存活和增殖增加，以及放松对各种细胞类型的细胞周期和基因组完整性的控制。另一方面，在一些模型系统中，Akt促进末梢分化。我推测，其他细胞因子的状态决定了激活的Akt是否有助于肿瘤发生或分化。由于Akt在正常细胞中的多效性，与Akt合作的肿瘤发生事件可能是比Akt本身更容易处理的治疗靶点。我们已经建立了一个模型系统，其中Akt单独激活不能引起转化，但可以与其他遗传事件合作。携带这些事件的细胞可以很容易地通过在融合培养中形成病灶的能力来区分。我们已经确定了Raf的积累就是这样一个事件：Akt和Raf合作激活一些依赖Raf信号的下游组分。我们将研究Akt-Raf连接的机制，以及这一合作过程中必不可少的下游事件。在同一系统中，我们还将使用无偏遗传筛选来识别可能在致癌转化中与活化Akt合作的其他遗传事件。我们在插入诱变方面获得了宝贵的经验，为基因发现项目奠定了基础。我们将使用一种改良的逆转录病毒载体进行全基因组插入突变，该载体携带一个面向宿主DNA的启动子，驱动宿主基因的全长、截断或反义产物的产生。载体被设计成允许启动子的切除，允许启动子插入作为转化表型的原因的明确验证。我们将鉴定与Akt合作转化的插入事件，并进一步研究受影响蛋白在转化和分化中的作用，包括分析与Akt的直接相互作用以及Raf通路的组分。我们将研究新特征因子在各种已知上调Akt的癌基因转化中的作用。这些因素在人类癌症中的地位将通过RNA和组织阵列进行研究。从长远来看，该项目将确定癌症治疗的潜在靶点和标记物，并为致癌转化的机制提供见解。